Coya Therapeutics, Inc. (COYA) stock
COYANasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 10, 2026Score 7/3017% above fair value
$3.09+0.07 (+2.32%)
Close on Nov 18, 2026Market cap $72.48MP/E –Yield –
Coya Therapeutics operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Coya Therapeutics's operating income for the twelve months ending Sep 30, 2026 was -$31.67M. For fiscal 2025 it was -$22.56M. The highest annual figure on record is -$4.87M in fiscal 2021.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$22.56M | – |
| FY2024 | Dec 31, 2024 | -$17.25M | – |
| FY2023 | Dec 31, 2023 | -$7.90M | – |
| FY2022 | Dec 31, 2022 | -$9.81M | – |
| FY2021 | Dec 31, 2021 | -$4.87M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$10.95M | – |
| Q2 FY2026 | Jun 30, 2026 | -$7.05M | – |
| Q1 FY2026 | Mar 31, 2026 | -$7.64M | – |
| Q4 FY2025 | Dec 31, 2025 | -$6.03M | – |
| Q3 FY2025 | Sep 30, 2025 | -$2.43M | – |
| Q2 FY2025 | Jun 30, 2025 | -$6.41M | – |
| Q1 FY2025 | Mar 31, 2025 | -$7.68M | – |
| Q4 FY2024 | Dec 31, 2024 | -$4.08M | -324.8% |
| Q3 FY2024 | Sep 30, 2024 | -$4.45M | – |
| Q2 FY2024 | Jun 30, 2024 | -$3.24M | – |
| Q1 FY2024 | Mar 31, 2024 | -$5.48M | – |
| Q4 FY2023 | Dec 31, 2023 | $1.82M | – |
| Q3 FY2023 | Sep 30, 2023 | -$3.56M | – |
| Q2 FY2023 | Jun 30, 2023 | -$3.25M | – |
| Q1 FY2023 | Mar 31, 2023 | -$2.90M | – |
| Q4 FY2022 | Dec 31, 2022 | -$2.00M | – |
| Q3 FY2022 | Sep 30, 2022 | -$2.66M | – |
| Q2 FY2022 | Jun 30, 2022 | -$3.45M | – |
| Q1 FY2022 | Mar 31, 2022 | -$1.70M | – |
See a number that looks wrong?